A Randomized Controlled Trial of Seroconversion After 20 Mg versus 40 mg Intramuscular Hepatitis B Virus Vaccination in Patients with Chronic Kidney Disease Stage 3

Krairittichai, U.; Sethakarun, S.

Journal of the Medical Association of Thailand 100(Suppl 1): S1-S7

2017


ISSN/ISBN: 0125-2208
PMID: 29926711
Document Number: 9225
There is as yet no guideline for hepatitis B virus (HBV) vaccination in chronic kidney disease (CKD). There is also insufficient evidence to support the theory that the immune response to a double dose (40 μg) of HBV vaccine is greater than that achieved by the standard dose (20 μg). To compare seroconversion of the four-dose regimen (at 0, 1, 2, 6 months) of intramuscular recombinant DNA HBV vaccination using the standard 20 μg with that of 40 μg in patients with CKD stage 3. This study included 39 patients with CKD stage 3 who had neither history of HBV vaccination nor Rates of seroconversion in the 20 μg versus the 40 μg groups at the 2nd, 6th, 7th, 12th month were 50.0%:52.6% (p = 0.869), 65.0%:100.0% (p = 0.004), 95.0%:100.0% (p = 0.323) and 80.0%:100.0% (p = 0.040) respectively. Six months after completing the vaccination, some patients (20.0%) in the 20 μg group had lost their immune response while all in the 40 μg group still maintained their seroconversion. During the study, there was no significant change in eGFR in the two groups (p>0.05), and minor adverse effects including local pain, malaise, fatigue, and dizziness were not significantly different between the two groups. Seroconversion rates of the two groups were not significantly different after completion of HBV vaccination, but

Document emailed within 1 workday
Secure & encrypted payments